# OnCo record nct04014205 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04014205/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04014205", "NCT04014205" ;
  schema:name "A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies"@en ;
  schema:description "A phase 1/2 trial of Orelabrutinib in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04014205/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04014205> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2019-11-18" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/orelabrutinib/> ;
  onco:companies <https://onco.cc/companies/innocare/> .